IDEXX Laboratories, Inc. (IDXX) Stake Decreased by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company trimmed its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 18.8% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 90,798 shares of the company’s stock after selling 20,994 shares during the quarter. The Manufacturers Life Insurance Company owned about 0.10% of IDEXX Laboratories worth $14,656,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the company. Wellington Management Group LLP acquired a new position in shares of IDEXX Laboratories during the 1st quarter worth $15,851,000. FMR LLC raised its holdings in shares of IDEXX Laboratories by 1,293.2% during the 1st quarter. FMR LLC now owns 36,419 shares of the company’s stock worth $5,630,000 after buying an additional 33,805 shares in the last quarter. Teachers Advisors LLC raised its holdings in shares of IDEXX Laboratories by 38.4% during the 1st quarter. Teachers Advisors LLC now owns 184,963 shares of the company’s stock worth $28,597,000 after buying an additional 51,359 shares in the last quarter. Global X Management Co. LLC raised its holdings in shares of IDEXX Laboratories by 44.6% during the 1st quarter. Global X Management Co. LLC now owns 1,047 shares of the company’s stock worth $162,000 after buying an additional 323 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in shares of IDEXX Laboratories by 20.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 326,957 shares of the company’s stock worth $50,550,000 after buying an additional 55,939 shares in the last quarter. Hedge funds and other institutional investors own 87.58% of the company’s stock.

In related news, Chairman Jonathan W. Ayers sold 13,000 shares of the stock in a transaction dated Monday, August 28th. The shares were sold at an average price of $150.79, for a total value of $1,960,270.00. Following the completion of the transaction, the chairman now owns 1,044,034 shares of the company’s stock, valued at approximately $157,429,886.86. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Lawrence D. Kingsley purchased 2,000 shares of the stock in a transaction that occurred on Thursday, August 3rd. The stock was acquired at an average cost of $151.76 per share, with a total value of $303,520.00. Following the acquisition, the director now owns 3,344 shares in the company, valued at approximately $507,485.44. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 151,734 shares of company stock valued at $23,436,626. 2.77% of the stock is owned by insiders.

A number of equities analysts have recently commented on the company. Zacks Investment Research cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday. BidaskClub raised IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a report on Friday, June 23rd. Bank of America Corporation raised IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $175.00 price target for the company in a report on Wednesday, August 23rd. CL King raised IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $200.00 price target for the company in a report on Friday, July 28th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $185.00 target price on shares of IDEXX Laboratories in a report on Friday, July 14th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $174.00.

Shares of IDEXX Laboratories, Inc. (IDXX) opened at 163.05 on Thursday. The stock has a 50 day moving average price of $157.67 and a 200 day moving average price of $160.10. The firm has a market cap of $14.23 billion, a PE ratio of 56.09 and a beta of 0.48. IDEXX Laboratories, Inc. has a 52 week low of $102.45 and a 52 week high of $173.01.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Tuesday, August 1st. The company reported $0.95 EPS for the quarter, beating the consensus estimate of $0.85 by $0.10. IDEXX Laboratories had a net margin of 14.13% and a negative return on equity of 473.46%. The business had revenue of $508.90 million during the quarter, compared to the consensus estimate of $502.44 million. During the same quarter in the prior year, the firm earned $0.74 EPS. The business’s revenue was up 9.1% on a year-over-year basis. Equities analysts expect that IDEXX Laboratories, Inc. will post $3.18 earnings per share for the current year.

WARNING: This news story was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of

Several other large investors also recently added to or reduced their stakes in the company. Wellington Management Group LLP acquired a new position in shares of IDEXX Laboratories during the 1st quarter worth $15,851,000. FMR LLC raised its holdings in shares of IDEXX Laboratories by 1,293.2% during the 1st quarter. FMR LLC now owns 36,419 shares of the company’s stock worth $5,630,000 after buying an additional 33,805 shares in the last quarter. Teachers Advisors LLC raised its holdings in shares of IDEXX Laboratories by 38.4% during the 1st quarter. Teachers Advisors LLC now owns 184,963 shares of the company’s stock worth $28,597,000 after buying an additional 51,359 shares in the last quarter. Global X Management Co. LLC raised its holdings in shares of IDEXX Laboratories by 44.6% during the 1st quarter. Global X Management Co. LLC now owns 1,047 shares of the company’s stock worth $162,000 after buying an additional 323 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in shares of IDEXX Laboratories by 20.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 326,957 shares of the company’s stock worth $50,550,000 after buying an additional 55,939 shares in the last quarter. Hedge funds and other institutional investors own 87.58% of the company’s stock.

In related news, Chairman Jonathan W. Ayers sold 13,000 shares of the stock in a transaction dated Monday, August 28th. The shares were sold at an average price of $150.79, for a total value of $1,960,270.00. Following the completion of the transaction, the chairman now owns 1,044,034 shares of the company’s stock, valued at approximately $157,429,886.86. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Lawrence D. Kingsley purchased 2,000 shares of the stock in a transaction that occurred on Thursday, August 3rd. The stock was acquired at an average cost of $151.76 per share, with a total value of $303,520.00. Following the acquisition, the director now owns 3,344 shares in the company, valued at approximately $507,485.44. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 151,734 shares of company stock valued at $23,436,626. 2.77% of the stock is owned by insiders.

A number of equities analysts have recently commented on the company. Zacks Investment Research cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday. BidaskClub raised IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a report on Friday, June 23rd. Bank of America Corporation raised IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $175.00 price target for the company in a report on Wednesday, August 23rd. CL King raised IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $200.00 price target for the company in a report on Friday, July 28th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $185.00 target price on shares of IDEXX Laboratories in a report on Friday, July 14th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $174.00.

Shares of IDEXX Laboratories, Inc. (IDXX) opened at 163.05 on Thursday. The stock has a 50 day moving average price of $157.67 and a 200 day moving average price of $160.10. The firm has a market cap of $14.23 billion, a PE ratio of 56.09 and a beta of 0.48. IDEXX Laboratories, Inc. has a 52 week low of $102.45 and a 52 week high of $173.01.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Tuesday, August 1st. The company reported $0.95 EPS for the quarter, beating the consensus estimate of $0.85 by $0.10. IDEXX Laboratories had a net margin of 14.13% and a negative return on equity of 473.46%. The business had revenue of $508.90 million during the quarter, compared to the consensus estimate of $502.44 million. During the same quarter in the prior year, the firm earned $0.74 EPS. The business’s revenue was up 9.1% on a year-over-year basis. Equities analysts expect that IDEXX Laboratories, Inc. will post $3.18 earnings per share for the current year.

WARNING: This news story was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://ledgergazette.com/2017/10/19/idexx-laboratories-inc-idxx-stake-decreased-by-the-manufacturers-life-insurance-company.html.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply